52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Verily Forms Strategic Alliances With Novartis, Otsuka, Pfizer And Sanofi To Transform Clinical Research
Otsuka announces results of phase 3 data on tolvaptan
Otsuka's 9-month group operating profit seen at about 28 bln yen - Nikkei
OTSUKA CORPORATION is a Japan-based company mainly engaged in the sale of system equipment, the installation support and maintenance services. The Company operates through two business segments. System Integration segment conducts consulting, hardware and software sales, contract software development, equipment installation and network construction. Service & Support segment provides office supply, maintenance services, as well as business support services. The Company is also involved in the car maintenance business and insurance business.
Otsuka Shokai Honsha Bldg.
President, Chief Director of Marketing, Representative Director
Head Senior Managing Executive Officer, Chief Director of Sales, Deputy Chief Director of Marketing, Director
Senior Managing Executive Officer, Deputy Chief Director of Sales, Director of CAD Promotion, Manager of CAD, Director
Head Senior Managing Executive Officer, Director of Tanomeeru Business, Director of Tanomeeru Information, Director of Tanomeeru Marketing, Director of Logistics Promotion, Director
Managing Executive Officer, Chief Director of Business Administration, Director of Human Resources Development, Director
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Verily, Novartis, Otsuka, Pfizer And Sanofi:
* Says primary and key secondary endpoints were positive for tolvaptan versus placebo in an additional phase 3 clinical trial
Novartis has won U.S. Food and Drug Administration approval for Kisqali to treat postmenopausal women who have a difficult-to-treat form of breast cancer, challenging U.S. rival Pfizer's Ibrance.
Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.